Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | group enriched outside the brain (monocytes) | 0.10 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 2 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 11103
Sealed predictions
- CD300LB in dopamine neurons, braak-0.56 (p 0.116) → -0.09 (p 0.825)receipt 11109
Swarm cases
receipt 11109: CD300LB in dopamine neurons, braak
- power
- full sample -0.31 (p 0.218, n 18), 95% CI -0.68 to +0.19. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.29 (p 0.243, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.51 (p 0.031, n 18). not the mix.
- skeptic
- leave-one-out range -0.43 to -0.21, sign flips 0; without severely affected donors -0.31 (p 0.218, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CD300LB in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts